Proteomics

Dataset Information

0

LC-MS3 analysis of Herc1-knockout mouse MLL/AF9 acute myeloid leukemia cells


ABSTRACT: Our CRISPR-based pharmacogenomic screening identified the E3 ubiquitin ligase Herc1 as a key modulator of sensitivity to cytarabine (Ara-C) chemotherapy in the MLL/AF9 (MA) mouse AML model both in vitro and in vivo. To identify the intracellular proteins whose abundance is modulated by Herc1, we performed comparative LC-MS3 analysis of in vitro-cultured MA mouse AML cells that were transduced with either a small-guide RNA targeting Herc1 (i.e., CRISPR-mediated Herc1-knockout) or a control non-targeting small-guide RNA, at steady state or after brief exposure to Ara-C (200 nMol for 6 hours).

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Mus Musculus (mouse)

DISEASE(S): Acute Leukemia

SUBMITTER: François Mercier  

LAB HEAD: Francois Mercier

PROVIDER: PXD054402 | Pride | 2024-08-08

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
M-TMT-F1.raw Raw
M-TMT-F2.raw Raw
M-TMT-F3.raw Raw
M-TMT-F4.raw Raw
M-TMT-F5.raw Raw
Items per page:
1 - 5 of 10
altmetric image

Publications


<h4>Abstract</h4>For several decades, induction therapy with nucleoside analogs, in particular cytarabine (Ara-C) and, to a lesser extent, fludarabine, has been the standard of care for patients diagnosed with acute myeloid leukemia (AML). However, the antitumor efficacy of nucleoside analogs is often limited by intrinsic and acquired drug resistance, thereby leading to poor therapeutic response and suboptimal clinical outcomes. In this study, we used genome-wide CRISPR-based pharmacogenomic scr  ...[more]

Similar Datasets

2017-06-09 | GSE94840 | GEO
2024-08-02 | GSE273667 | GEO
2013-03-06 | E-GEOD-44857 | biostudies-arrayexpress
2013-03-06 | GSE44830 | GEO
2013-03-06 | GSE44857 | GEO
2013-03-06 | E-GEOD-44830 | biostudies-arrayexpress
2021-11-11 | PXD022488 | Pride
2022-02-16 | GSE185846 | GEO
2015-02-15 | ST000288 | MetabolomicsWorkbench
2016-01-02 | GSE52919 | GEO